Why the study?
Does killed poliovaccine compared to attenuated poliovaccine or no poliovaccine improve serological response and reduce viral excretion following live virus challenge in infants?
Does killed poliovaccine compared to attenuated poliovaccine or no poliovaccine improve serological response and reduce viral excretion following live virus challenge in infants?
Killed poliovaccine in infancy reduces the duration and amount of viral excretion upon subsequent exposure to live virus, though it does not prevent infection as effectively as oral attenuated vaccine.
Killed poliovaccine reduces fecal viral duration and titre after live challenge in infants; extends evidence for limiting transmission without blocking infection.
Quadruple vaccine containing 75 D antigen units of killed type 1 poliovirus was given to children at ages 2, 3 and 4 months followed by a booster dose at 15 months. The serological response to the primary course was difficult to assess owing to maternal antibody. Antibody titres to the type 1 component after the booster dose were very satisfactory and about 10 times higher than those observed in a similar group of children given attenuated vaccine. Response to the poliovirus types 2 and 3 in the quadruple vaccine was less satisfactory. Graded doses of attenuated poliovirus type 1 were fed to the children 2 months after the primary course and 1 month after the booster dose. Children who had received no poliovaccine and children immunized with attenuated vaccine were included for comparison. Immunization with killed vaccine did not greatly affect the size of the minimal infecting dose of live virus but reduced both the duration of the subsequent infection and the titre of virus in the faeces. The epidemiological significance of these findings is discussed.
No takes yet. Share an insight, caveat, or question.
Henry et al. (1966) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: